Document Detail


Current and future therapeutic options for persistent pulmonary hypertension in the newborn.
MedLine Citation:
PMID:  20528642     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Persistent pulmonary hypertension of the newborn (PPHN) is a potentially life-threatening condition that is characterized by supra-systemic pulmonary vascular resistance causing right-to-left shunting through the ductus arteriosus and/or foramen ovale, leading to a vicious cycle of hypoxemia, acidosis and further pulmonary vasoconstriction. Advances in neonatology including surfactant instillation, high-frequency ventilation, extracorporeal membrane oxygenation and, most importantly, inhaled nitric oxide (INO), have revolutionized the management of PPHN. However, given that INO does not improve oxygenation in a significant proportion (30-40%) of cases, there is an urgent need to consider other therapeutic options for PPHN. The issue is more important for developing nations with a higher PPHN-related health burden and limited resources. This article discusses the evidence about INO in term and preterm neonates in brief, and focuses mainly on the potential alternative drugs in the management of PPHN.
Authors:
Shripada Rao; David Bartle; Sanjay Patole
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert review of cardiovascular therapy     Volume:  8     ISSN:  1744-8344     ISO Abbreviation:  Expert Rev Cardiovasc Ther     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-06-09     Completed Date:  2010-10-04     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101182328     Medline TA:  Expert Rev Cardiovasc Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  845-62     Citation Subset:  IM    
Affiliation:
Department of Neonatal Paediatrics, KEM Hospital for Women, Bagot road, Subiaco, Perth 6008, Western Australia, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Inhalation
Animals
Animals, Newborn
Antihypertensive Agents / administration & dosage,  economics,  pharmacology,  therapeutic use
Humans
Infant, Newborn
Infant, Premature
Nitric Oxide / administration & dosage,  economics,  pharmacology,  therapeutic use
Persistent Fetal Circulation Syndrome / drug therapy*,  physiopathology,  therapy*
Treatment Outcome
Vasodilator Agents / administration & dosage,  economics,  pharmacology,  therapeutic use
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Vasodilator Agents; 10102-43-9/Nitric Oxide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients.
Next Document:  Massive pulmonary embolism: review of management strategies with a focus on catheter-based technique...